Salvatore Siena

Salvatore Siena at the University of Milan is a leading authority on EGFR-targeted therapy in colorectal cancer, contributing fundamental research demonstrating that RAS mutations predict resistance to cetuximab and panitumumab. His work on extended RAS testing became the foundation for patient selection in anti-EGFR therapy and established the principle of comprehensive biomarker testing before EGFR inhibitor use. He has pioneered liquid biopsy approaches to monitor clonal evolution during anti-EGFR therapy in CRC. His translational research bridges genomics, resistance mechanisms, and clinical decision-making.